PAP
RCUS icon

Persistent Asset Partners’s Arcus Biosciences RCUS Stock Holding History

Persistent Asset Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Sell
57,048
-3,155
-5% -$78K 0.52% 44
2026
Q1 		$1.3M Buy
+60,203
New +$1.3M 0.48% 52
2025
Q1 		– Sell
-50,213
Closed -$648K – 205
2024
Q4 		$648K Buy
+50,213
New +$820K 0.54% 52

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Persistent Asset Partners's RCUS Position: Q2 2026 in Review

Persistent Asset Partners reduced its Arcus Biosciences (RCUS) stake by 5.2% in Q2 2026, selling an estimated $78K and leaving 57,048 shares worth $1.76M. The position accounts for 0.52% of the portfolio, ranked #44.

Persistent Asset Partners first reported a position in RCUS in Q4 2024 and has held it in 3 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Persistent Asset Partners held 57,048 shares of Arcus Biosciences worth $1.76M as of Q2 2026.
  • Persistent Asset Partners sold 3,155 Arcus Biosciences shares in Q2 2026, an estimated $78K.
  • Arcus Biosciences made up 0.52% of Persistent Asset Partners's portfolio in Q2 2026, its #44 holding.
  • Persistent Asset Partners first reported a position in Arcus Biosciences in Q4 2024 and has held it in 3 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.